These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 11464876

  • 1. Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group.
    George RE, Variend S, Cullinane C, Cotterill SJ, McGuckin AG, Ellershaw C, Lunec J, Pearson AD, United Kingdom Children Cancer Study Group.
    Med Pediatr Oncol; 2001 Jan; 36(1):169-76. PubMed ID: 11464876
    [Abstract] [Full Text] [Related]

  • 2. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S, Umehara S, Gerbing RB, Stram DO, Brodeur GM, Seeger RC, Lukens JN, Matthay KK, Shimada H.
    Cancer; 2001 Nov 15; 92(10):2699-708. PubMed ID: 11745206
    [Abstract] [Full Text] [Related]

  • 3. MYCN protein expression as a predictor of neuroblastoma prognosis.
    Chan HS, Gallie BL, DeBoer G, Haddad G, Ikegaki N, Dimitroulakos J, Yeger H, Ling V.
    Clin Cancer Res; 1997 Oct 15; 3(10):1699-706. PubMed ID: 9815553
    [Abstract] [Full Text] [Related]

  • 4. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
    Shimada H, Nakagawa A, Peters J, Wang H, Wakamatsu PK, Lukens JN, Matthay KK, Siegel SE, Seeger RC.
    Cancer; 2004 Oct 15; 101(8):1873-81. PubMed ID: 15386308
    [Abstract] [Full Text] [Related]

  • 5. Heterogeneity of MYCN amplification in a child with stroma-rich neuroblastoma (ganglioneuroblastoma).
    Lorenzana AN, Zielenska M, Thorner P, Gerrie B, Weitzman S, Squire J.
    Pediatr Pathol Lab Med; 1997 Oct 15; 17(6):875-83. PubMed ID: 9353827
    [Abstract] [Full Text] [Related]

  • 6. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group.
    Bown N, Lastowska M, Cotterill S, O'Neill S, Ellershaw C, Roberts P, Lewis I, Pearson AD, U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group.
    Med Pediatr Oncol; 2001 Jan 15; 36(1):14-9. PubMed ID: 11464868
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
    Altungoz O, Aygun N, Tumer S, Ozer E, Olgun N, Sakizli M.
    Cancer Genet Cytogenet; 2007 Jan 15; 172(2):113-9. PubMed ID: 17213019
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Prognostic significance of MYCN amplification in children neuroblastic tumors].
    Niu H, Xu T, Wang F, Chen Z, Gao Q, Yi P, Xia J.
    Zhonghua Bing Li Xue Za Zhi; 2015 Feb 15; 44(2):111-7. PubMed ID: 25916642
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. High incidence of MYCN amplification in a Moroccan series of neuroblastic tumors: comparison to current biological data.
    Tabyaoui I, Tahiri-Jouti N, Serhier Z, El Maani K, Cherkaoui S, Al Zemmouri M, Othmani MB, Zamiati S.
    Diagn Mol Pathol; 2013 Jun 15; 22(2):112-8. PubMed ID: 23628823
    [Abstract] [Full Text] [Related]

  • 16. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
    Krams M, Hero B, Berthold F, Parwaresch R, Harms D, Rudolph P.
    Cancer; 2002 Feb 01; 94(3):854-61. PubMed ID: 11857322
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
    Tonini GP, Boni L, Pession A, Rogers D, Iolascon A, Basso G, Cordero di Montezemolo L, Casale F, Pession A, Perri P, Mazzocco K, Scaruffi P, Lo Cunsolo C, Marchese N, Milanaccio C, Conte M, Bruzzi P, De Bernardi B.
    J Clin Oncol; 1997 Jan 01; 15(1):85-93. PubMed ID: 8996128
    [Abstract] [Full Text] [Related]

  • 19. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
    Spitz R, Hero B, Skowron M, Ernestus K, Berthold F.
    Eur J Cancer; 2004 Dec 01; 40(18):2753-9. PubMed ID: 15571958
    [Abstract] [Full Text] [Related]

  • 20. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
    George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L, Brodeur GM, Castleberry RP, Look AT.
    J Clin Oncol; 2005 Sep 20; 23(27):6466-73. PubMed ID: 16116152
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.